Day: March 27, 2023

Professional Diversity Network Acquires Additional Equity Interest in RemoteMore USA, Inc.

Written by Customer Service on March 27, 2023. Posted in Mergers And Acquisitions.

CHICAGO, March 27, 2023 (GLOBE NEWSWIRE) — Professional Diversity Network, Inc. (NASDAQ:IPDN) (“PDN” or the “Company”), a developer and operator of online and in-person networks that provide access to networking, training, educational and employment opportunities for diverse individuals, announced the acquisition of additional 20% of equity interest in RemoteMore USA, Inc. (“RemoteMore”) on March 23, 2023, an online platform specializing in remote-hiring of software developers, increasing PDN’s ownership position in RemoteMore to approximately 66% after the transaction. Recognizing the unstoppable trend of remote working and the surged demand of a curated workforce pool, PDN purchased approximately 46% of equity interest in RemoteMore back in September 2021. Since that acquisition, RemoteMore has continuously grown its revenue...

Imperial Petroleum Announces Management Estimate of Net Asset Value Per Share- $1.39

Written by Customer Service on March 27, 2023. Posted in Public Companies.

ATHENS, Greece, March 27, 2023 (GLOBE NEWSWIRE) — Imperial Petroleum Inc. (Nasdaq: IMPP) (the “Company”), a ship-owning company providing petroleum products, crude oil, and drybulk seaborne transportation services, announced today that at March 27, 2023 the Company’s management, estimates Imperial Petroleum Inc’s Net Asset Value (“NAV”) to be $338.6 million, which is approximately 717% above its current market capitalization. The NAV which includes total outstanding cash of $142.2 million is increasing daily on account of the record net cashflow contributed by our tankers. This translates into a NAV of $1.39 per common share currently outstanding and $1.17 per common share on a fully diluted basis (assuming exercise of all outstanding warrants for cash). NET ASSET VALUE (“NAV”) The estimated NAV represents a snapshot in time as...

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Written by Customer Service on March 27, 2023. Posted in Earnings Releases And Operating Results.

Data to be presented at AACR demonstrate significant SP-3164 anticancer activity in both non-Hodgkin Lymphoma and Multiple Myeloma cell lines and animal models Targeted protein degrader SP-3164 on track for IND submission in first half of 2023 with clinical trial to begin in second half of 2023 HOUSTON, March 27, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and 12 months ended December 31, 2022 and provided a business update. Financial HighlightsCash and cash equivalents were $12.1 million as of December 31, 2022, compared with $29.2 million as of December 31, 2021. Subsequent to the close...

Timbercreek Financial ranks on The Globe and Mail’s fourth-annual Women Lead Here benchmark of executive gender diversity for a third year

Written by Customer Service on March 27, 2023. Posted in Public Companies.

TORONTO, March 27, 2023 (GLOBE NEWSWIRE) — Timbercreek Financial (“Timbercreek”) is pleased to announce it has been included on The Globe and Mail’s 2023 Report on Business magazine’s Women Lead Here list for a third straight year. This annual editorial benchmark identifies top-notch Canadian businesses with the highest executive gender diversity. The ranking companies have made tangible and organizational progress related to executive gender parity. This benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to determine Canadian corporations with the highest degree of gender diversity among executive ranks. “It is a privilege to be among the most gender-diverse corporations in Canada for a third consecutive year,” said Blair Tamblyn, CEO of Timbercreek. “We are extremely...

LPL Financial Welcomes SC Financial Group

Written by Customer Service on March 27, 2023. Posted in Public Companies.

CHARLOTTE, N.C., March 27, 2023 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that SC Financial Group has joined LPL Financial’s broker-dealer, RIA and custodial platforms. The team reported having served approximately $220 million in advisory, brokerage and retirement plan assets*, and joins LPL from Cadaret Grant & Co, now part of the Atria Group. Financial advisors Shane Cloninger and Susan Carter, who has since retired, founded the Bellevue, Wash.,- based practice in 2008 with a mission to deeply understand and foster each client’s true needs and financial goals. The multigenerational practice has evolved over the years to include fellow advisors Robert Davis, Rumesh Senanayake and Alex Carter, Susan’s son. The team focuses heavily on retirement income strategies, investor education and portfolio management, often...

Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

Written by Customer Service on March 27, 2023. Posted in Mergers And Acquisitions.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right (the “CVR”). The $1.85 per share upfront consideration represents a premium of approximately 75% to Jounce’s closing share price immediately prior to the March 14, 2023 public disclosure...

LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Written by Customer Service on March 27, 2023. Posted in Earnings Releases And Operating Results.

Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing, with data expected mid-year 2023 Phase 3 registrational trial of TP-03 in Chinese patients with Demodex blepharitis ongoing, with data expected in the fourth quarter of 2023 Entered into commercial agreement with Pfizer, with Pfizer opting into LianBio rights to RSV therapeutic candidate sisunatovir in LianBio territories Cash, cash equivalents and marketable securities of $302.4 million with runway through the end of 2024 SHANGHAI, China and PRINCETON, N.J., March 27, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the fourth quarter and year ended December...

Medigus: Viewbix Reports its Financial Results for 2022 with a 114% Growth in Revenues Totaling $97 Million

Written by Customer Service on March 27, 2023. Posted in Earnings Releases And Operating Results.

Viewbix is a subsidiary of Gix Internet whose results are consolidated with Medigus’ financial statements Tel Aviv, Israel, March 27, 2023 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that Viewbix Inc. (henceforth “Viewbix”) (OTC: VBIX), 76% owned by Medigus’ subsidiary Gix Internet, (henceforth “Gix”) (42.25% owned by Medigus) (TASE: GIX), a global marketing technology (MarTech) solutions company for online performance-based-marketing, reported its financial results for the fourth quarter and the fiscal year ended December 31, 2022. Key highlights for the fourth quarter and the fiscal year ended December 31, 2022, include:Revenues for the fiscal year ended December 31,...

Skyline Announces Continued Improvement in Operational Results During the Year Ended December 31, 2022

Written by Customer Service on March 27, 2023. Posted in Earnings Releases And Operating Results.

TORONTO, March 27, 2023 (GLOBE NEWSWIRE) — Skyline Investments Inc. (the “Company” or “Skyline”) (TASE: SKLN), a Canadian company that specializes in hotel real estate investments in the United States and Canada, published its results for the year ended December 31, 2022. SUMMARY OF FINANCIAL RESULTSC$000’s 2022 2021 2020 NOI1 from Hotels & Resorts 27,535 33,081 11,359 NOI from Hotels & Resorts Margin 21% 26% 12% Same Asset Revenue 129,287 90,150 55,207 Same Asset NOI1 25,904 22,184 3,392 Same Asset NOI Margin 20% 25% 6% Adjusted EBITDA2 19,727 24,501 7,884 Adjusted EBITDA Margin 15% 18% 6% Net Income (loss) (2,025) 29,578 (18,637) FFO1 9,285 12,312 (3,761) Shareholders’ Equity 280,458 266,249 226,044 Q4 and 2022 Highlights2022...

POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

Written by Customer Service on March 27, 2023. Posted in Earnings Releases And Operating Results.

Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT’s PNT2002 and PNT2003 product candidates Completed enrollment for randomization phase of PNT2002’s phase 3 SPLASH registrational trial, with top line data expected in the second half of 2023 INDIANAPOLIS, March 27, 2023 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. “POINT continued to make significant progress in 2022, enabled by our company’s deep expertise in radioligands and our vertically integrated, highly differentiated radioligand platform,” said Joe McCann,...

Day: March 27, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice